Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 6/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | BAD | Q92934 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
| ▸ | CTRC | Q99895 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL887289 | 0.83 | PARP1 (0.40) | PARP1CES1BCL2L1BADNOS3 | |
| SCHEMBL887350 | 0.74 | PARP1 (0.34) | PARP1CES1GRIA1GRIA2GRIA3 | |
| SCHEMBL1284960 | 0.66 | BCL2L1 (0.58) | PARP1CES1BCL2L1BADNOS3 | |
| SCHEMBL1278375 | 0.65 | BCL2L1 (0.52) | PARP1CES1BCL2L1BADNOS3 | |
| SCHEMBL9461283 | 0.62 | BCL2L1 (0.50) | PARP1CES1BCL2L1BADNOS3 | |
| SCHEMBL16239399 | 0.62 | BCL2L1 (0.52) | PARP1CES1BCL2L1BADGRIA1 | |
| SCHEMBL20112700 | 0.62 | CES1 (0.52) | PARP1CES1BCL2L1BADNOS3 | |
| SCHEMBL13002367 | 0.62 | CES1 (0.46) | PARP1CES1BCL2L1BADNOS3 | |
| SCHEMBL6557292 | 0.62 | GPR84 (0.44) | PARP1CES1BCL2L1BADGRIA1 | |
| SCHEMBL887378 | 0.62 | CES1 (0.39) | PARP1CES1BCL2L1BADNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902207-B2 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7902207-B2 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20070142639-A1 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070142639-A1 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142639-A1 | Process for production of amines | SMS, CCNT1, PEAK1 | PARP1 2047/4885CES1 2520/4885BCL2L1 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.